The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease
The integrated analysis replicated and corroborated the good safety profile observed in the individual studies. Despite the larger sample size, no new safety signals emerged. Long-term exposure to pridopidine, up to 6.5 years in open-label extension studies, revealed no new safety concerns, supporting its potential for long-term use in patients with HD.
Authors
- Martin Niethammer (ORCID: https://orcid.org/0000-0001-6343-5886)
- Andrew M. Tan (ORCID: https://orcid.org/0000-0002-0099-8814)
- Andrés Cruz-Herranz (ORCID: https://orcid.org/0000-0002-9629-1492)
- Katrin Spiegel
- Kelly S. Chen (ORCID: https://orcid.org/0000-0003-1473-864X)
- Michael R. Hayden (ORCID: https://orcid.org/0000-0001-5159-1419)
- Michal Geva (ORCID: https://orcid.org/0000-0002-6949-0963)
- Leehee Navon-Perry
- Yael Chava Cohen (ORCID: https://orcid.org/0000-0002-9061-7287)
- Henk Schuring
- Yigal Paul Goldberg
- Gabriele Hecker-Barth
Institutions
- Northwell Health (US)
- University of British Columbia (CA)
- North Shore University Hospital (US)
- Yale University (US)
- Unilever (Netherlands) (NL)
Publication Details
- Journal
- CNS Drugs
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1007/s40263-025-01171-x
- Citations
- 5
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 4.03